Ecolectro | $10,500,000 | (Nov 15, 2024)
Workflow | $3,000,000 | (Nov 15, 2024)
runQL | $1,600,000 | (Nov 15, 2024)
Certified by Founder
Lodge
Bryleos
start up
United States
- Johnson City, Tennessee
- 14/06/2023
- Seed
- $5,000,000
Early clinical stage therapeutics company developing BNAD101, a patent-pending oral composition of NAD+ clinically proven to increase intracellular NAD+. BNAD101 is a potential high-value medicine to treat challenging and costly neurological disorders.
In 2022, the Company completed its double-blind, placebo-controlled proof of concept study at the Institute of Systems Biology. The study of 60 healthy adults demonstrated BNAD101 had a 52% increase in intracellular NAD levels against placebo within just 5 days, effectively validating the potential of BNAD101 in treating not only chronic neurological conditions but conditions were swift response is critical.
Bryleos: More Life While Living
- Industry Biotechnology Research
- Website https://bryleos.com/
- LinkedIn https://www.linkedin.com/company/bryleos/
ELICIT PLANT | $48,000,000 | (Nov 15, 2024)
Sunthetics | $4,000,000 | (Nov 15, 2024)
Vaulted Deep | $32,300,000 | (Nov 15, 2024)
Serenity | $5,500,000 | (Nov 15, 2024)
Airbound | $1,700,000 | (Nov 15, 2024)
Influur | $10,000,000 | (Nov 15, 2024)
Naturbeads | $9,890,632 | (Nov 15, 2024)
TestSprite | $1,500,000 | (Nov 15, 2024)
Impilo | $11,500,000 | (Nov 15, 2024)